Another COVID-19 drug, based on monoclonal antibodies as the one used to treat former US President Donald Trump, is nearly ready and can be expected to be registered within the next three-five months, Logunov said at a meeting with Russian President Vladimir Putin. The treatment has proved to be 100% effective against COVID-19 in animal trials and is now entering the clinical trial stage on volunteers, he added.
The development of the chemical drug, on the other hand, is still at an early stage and trials on animals are required, Logunov said.
The development of the chemical drug, on the other hand, is still at an early stage and trials on animals are required, Logunov said.
"At the moment we have carried out an initial screening, and we have compounds... that are hits, leading compounds that will be optimized and tested in experiments on animals," Logunov explained.
Creating COVID-19 treatment drug takes more time than creating a drug based on monoclonal antibodies, Logunov added. He expressed hope that the drug will be registered by the end of 2022 after successful animal and clinical trials.